BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Allergy Therapeutics plc Extends Anapen(C) Distribution Agreement into UK and Ireland


9/19/2011 10:19:04 AM

September 19, 2011 -- Allergy Therapeutics plc (AIM: “AGY” or the “Company”), a fully integrated global specialty pharmaceutical company specialising in allergy vaccines, is pleased to announce that it has obtained the exclusive distribution rights in the UK and Ireland for the epinephrine pen auto injector, Anapen®, for a payment of £600,000. The agreement term is initially for 5 years and will commence on 1st November 2011.

Anapen®, produced by Lincoln Medical Limited, is indicated for the treatment of anaphylactic shock. Anaphylactic shock is a life threatening allergic reaction with increasing prevalence in all developed countries. Anapen® is the only epinephrine pen auto injector in the world with a 500 micrograms presentation. The 500 microgram presentation is indicated for people weighing above 65kg, giving Anapen® a strong competitive advantage.

The epinephrine pen auto injector market in the UK is valued at around £20 million and grew by 20% last year. Anapen® is already launched in the UK and Ireland and Allergy Therapeutics expects sales of up to £2 million in those countries during the next 12 months. Anapen® will be an important new product for Allergy’s UK sales force and is targeted at similar physicians to those prescribing the Company’s lead product Pollinex Quattro for the treatment of allergic conditions.

Allergy Therapeutics has been selling Anapen® in The Netherlands since September 2010 and has also received the exclusive rights to distribute Anapen® in Italy, Spain, Belgium, Poland, Argentina, Venezuela, Colombia and Chile, all countries with promising market potential. The Company expects to launch Anapen® in these countries during the next 12 months, subject to regulatory approvals.

For further information

Allergy Therapeutics +44 (0) 1903 845 820

Manuel Llobet, Chief Executive Officer

Ian Postlethwaite, Finance Director

www.allergytherapeutics.com

Nomura Code Securities - NOMAD +44 (0) 207 776 1200

Juliet Thompson/ Clare Terlouw

Financial Dynamics +44 (0) 207 831 3113

Jonathan Birt/ Susan Quigley

Victoria Foster Mitchell

Consultant

FD Santé

Holborn Gate, 26 Southampton Buildings

London, WC2A 1PB

D +44 (0)20 3077 0486

M +44 (0)7816 944 230

www.fd.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES